Agilent and BioNanomatrix to Develop Genetic Analysis System Using Nanoscale Whole Genome Imaging Technology
News Nov 06, 2007
BioNanomatrix will apply its nanoscale single molecule imaging technology to develop consumable chips and reagents, while Agilent will develop the measurement instrumentation platform for the system.
"This collaboration with Agilent provides us with the opportunity to join forces with a global life sciences leader to accelerate the development of our unique nanoscale whole genome imaging technology," said Dr. Michael Boyce-Jacino, chief executive officer of BioNanomatrix.
"We now have a partner with strong life sciences expertise and capabilities committed to working with us to develop key life-sciences applications, such as assays for genotoxicity and cytogenetics, as well as potentially DNA sequencing," he said.
BioNanomatrix is developing technology that enables nanoscale single molecule identification and analysis of the entire genome, delivering single-molecule sensitivity in a highly parallel format.
The company's patented analytic platform based on this technology has the potential to provide ultra-high resolution analyses of DNA. The two companies intend to collaborate closely in the development of an integrated system and applications.
Further details of the agreement were not disclosed.
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.